Lipid management in primary prevention: Challenges in the era of low LDL-c & novel therapies - PACE-CME

Lipid management in primary prevention Challenges in the era of low LDLc novel therapies

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Phase 3 study with oral semaglutide meets primary endpoint in high-risk T2D
Phase 3 study with oral semaglutide meets primary endpoint in high-risk T2D
ACC.25
Phase 3 study with oral semaglutide meets primary endpoint in high-risk T2D
- Darren K. McGuire, MD
Secondary prevention strategy led by nurses reduces MACE risk after an ACS
Secondary prevention strategy led by nurses reduces MACE risk after an ACS
ACC.25
Secondary prevention strategy led by nurses reduces MACE risk after an ACS
- Giulia Magnani, MD, PhD
What we can learn from registry data to improve lipid goal attainment
What we can learn from registry data to improve lipid goal attainment
Hyperlipidemia
What we can learn from registry data to improve lipid goal attainment
- Kausik Ray, MBChB, MD, MPhil
Promising results with oral Lp(a) inhibitor in phase 2 trial
Promising results with oral Lp(a) inhibitor in phase 2 trial
AHA 2024
Promising results with oral Lp(a) inhibitor in phase 2 trial
- Stephen Nicholls, FRACP, FACC, FESC, FAHA